Skip to content

Adhesive Materials for Continuous Glucose Monitoring Systems

Evaluation of Different Types of Adhesive Materials for Continuous Glucose Monitoring Systems in Subjects With Type 1 and Type 2 Diabetes Mellitus

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03340467
Enrollment
0
Registered
2017-11-13
Start date
2018-08-01
Completion date
2018-09-30
Last updated
2019-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

Within the present study 4 different band-aid/adhesive combinations will be tested in patients with type 1 diabetes and type 2 diabetes with regard to adherence to the body and allergic potential. The study period is set to 21 days following adhesive material placement to cover the maximum expected wear-time of the novel CGM system (14 days) plus an additional seven days to ensure that adhesive material is tested for a sufficient time-period and differences in adhesion can clearly be observed.

Interventions

DEVICECGM patch

Patient receives four CGM patches.

Sponsors

Medical University of Graz
CollaboratorOTHER
Metronom Health
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent obtained after being advised of the nature of the study * Male or female aged ≥18 years * Type 1 diabetes for at least 6 months according to the WHO definition or Type 2 diabetes for at least 6 months according to the WHO definition * Body Mass Index (BMI) \<45 kg/m² * Willing and able to wear 4 different band-aid/adhesive materials for the duration of the study and undergo all study procedures * HbA1c ≤86 mmol/mol

Exclusion criteria

* Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject * Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods * Any mental condition rendering the subject incapable of giving his consent * Subject is using any medication that significantly impacts immune response (oral steroids) * Has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study * Subject is actively enrolled in another clinical trial * Known severe hypersensitivity to adhesive or skin lesions that hinder band-aid application * Inability of the subject to comply with all study procedures * Inability of the subject to understand the subject information * Has children two years of age or younger * Vulnerable patients, patients deprived from liberty and patients with a physical or mental state altered by disease, age or disability which impacts their ability to defend their interests and for which protection measures are taken (protected majors as per French law).

Design outcomes

Primary

MeasureTime frameDescription
Survival rate21 days14 days survival rate of different models of CGM patches to fixate a CGM sensor system.

Secondary

MeasureTime frameDescription
Survival time21 daysSurvival time (time to peel-off) of different models of CGM patches to fixate a CGM sensor system
Attachment site reactions21 daysErythema, edema and blister formation according to ICDRG scoring system

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026